Glenn Tillotson is a consultant microbiologist working the pharmaceutical industry. He provides support for both medical affairs and commercialization programs for companies, most notably in the infectious disease area. He has had a number of senior roles in the pharmaceutical industry and was an integral member of the Cipro and Avelox teams while at Bayer. Since then he has been involved in several Clostridioides difficile programs. He is Editor in Chief of Expert Opinion in Anti-Infective Therapy journal.